Saturn V Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Saturn V Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-38,191	Closed	-$6.59M	–	19
2025 Q2	$6.59M	Sell	38,191 -161,073	-81%	-$26.2M	2.67%	16
2025 Q1	$31.1M	Buy	199,264 +287	+0.1%	+$41K	15.67%	1
2024 Q4	$27.4M	Sell	198,977 -1,308	-0.7%	-$172K	10.73%	2
2024 Q3	$29.9M	Buy	200,285 +87,061	+77%	+$11.8M	10.69%	1
2024 Q2	$15.4M	Buy	113,224 +9,796	+9%	+$1.33M	5.83%	5
2024 Q1	$15.6M	Sell	103,428 -28,331	-22%	-$4.04M	6.27%	7
2023 Q4	$16.6M	Buy	131,759 +19,286	+17%	+$1.92M	6.35%	6
2023 Q3	$10.5M	Buy	112,473 +34,031	+43%	+$3.18M	4.41%	12
2023 Q2	$7M	Buy	78,442 +1,232	+2%	+$107K	3.88%	13
2023 Q1	$8.28M	Buy	77,210 +8,806	+13%	+$1.01M	6.18%	10
2022 Q4	$7.95M	Buy	+68,404	New	+$7.94M	6.6%	6

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Saturn V Capital Management's ASND Position: Q3 2025 in Review

Saturn V Capital Management sold out of Ascendis Pharma A/S (ASND) in Q3 2025, closing a stake of 38,191 shares — an estimated $6.59M sold.

Saturn V Capital Management first reported a position in ASND in Q4 2022 and held it in 11 quarters. The position peaked at $31.1M in Q1 2025. 279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.

Saturn V Capital Management reported no remaining Ascendis Pharma A/S position as of Q3 2025 after selling out during the quarter.
Saturn V Capital Management sold 38,191 Ascendis Pharma A/S shares in Q3 2025, an estimated $6.59M.
Saturn V Capital Management first reported a position in Ascendis Pharma A/S in Q4 2022 and held it in 11 quarters.
Saturn V Capital Management's Ascendis Pharma A/S position peaked at $31.1M in Q1 2025.
279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.